Nutriband receives notice of allowance for new u.s. patent covering its transdermal abuse deterrent technology aversa™

Orlando, fla., feb. 07, 2025 (globe newswire) -- nutriband inc. (nasdaq:ntrb)(nasdaq:ntrbw), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it received a notice of allowance from the united states patent and trademark office (uspto) on february 3, 2025 for patent application 18/369,241, "abuse and misuse deterrent transdermal systems" which covers its aversa™ abuse deterrent technology.
NTRB Ratings Summary
NTRB Quant Ranking